Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

News Releases

  •   Email
  •   Print
  •   Share

  • Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk “smoldering” multiple myeloma to the full-blown disease, according to researchers from Dana-Farber.

Tags: MultipleMyeloma

  • An immunotherapy drug able to induce lasting remissions in classical Hodgkin lymphoma may be equally effective in patients with two rare, aggressive forms of non-Hodgkin lymphoma, results from Dana-Farber researchers shows.

Tags: Lymphoma

  • Despite an elevated risk of toxicity from chemotherapy, children with Down syndrome and acute lymphoblastic leukemia (ALL) did not experience higher rates of relapse or treatment-related mortality compared with other children treated on Dana-Farber ALL Consortium Protocols.

Tags: ChildhoodCancer, Leukemia

  • A study led by Dana-Farber researchers shows a combination of two targeted agents has demonstrated safety as well as encouraging signs of effectiveness in a clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia or mantle cell lymphoma.

Tags: Leukemia, Lymphoma

  • A significant percentage of lymphoma patients undergoing transplants with their own blood stem cells carry acquired genetic mutations that increase their risks of developing second hematologic cancers and dying from other causes, according to a study from Dana-Farber researchers.

Tags: StemCellTransplant, Lymphoma

  • A blood test can indicate whether some patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant and, if so, whether the transplant should involve high or moderate doses of chemotherapy and/or radiation therapy, according to a study by scientists at Dana-Farber.

Tags: StemCellTransplant

  • Researchers led by scientists at Dana-Farber say they have identified unique genomic changes that may be integral to testicular cancer development and explain why the great majority are highly curable with chemotherapy – unlike most solid tumors.

Tags: chemotherapy, Genomics, TargetedTherapy

  • William Sellers, MD, a widely-respected cancer researcher with deep experience in cancer genomics and therapeutic discovery, is returning to the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School as a faculty member.

Tags: Appointments, Genomics

  • New study led by Dana-Farber finds dinaciclib resensitizes triple-negative breast tumors to PARP inhibitor by impeding DNA repair in tumor cells. The Dinaciclib/PARP inhibitor combination will be tested in breast and ovarian cancer patients.

Tags: BreastCancer, OvarianCancer

  • In a new study, a group of Boston scientists, including researchers at Dana-Farber, offer a genetic explanation for the age-old conundrum of why cancer is more common in males than females.

Tags: BasicResearch, PopulationScience

Showing 1-10 of 735 items